Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

Summary

This phase I trial studies the side effects and best dose of tipifarnib and erlotinib hydrochloride in treating patients with solid tumors that have spread to other places in the body. Tipifarnib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2004-05-20

Primary completion

2008-05-07

Completion

2018-05-16

Drugs

Indications